[Expression and significance of CMTM5 and epidermal growth factor receptor in prostate cancer].
OBJECTIVE
To investigate the expression patterns of CKLF-like MARVEL transmembrane domain containing 5 (CMTM5), a novel tumor suppressor, and epidermal growth factor receptor (EGFR) in prostate cancer (PCa) tissues and cells and to analyze the relationship between CMTM5 and EGFR in PCa.


METHODS
The expression patterns of CMTM5 and EGFR in PCa tissues and cells were detected by immunohistochemistry and Western blot, respectively.


RESULTS
CMTM5 was highly expressed in 75% (27/36) of benigh prostatic hyperplasia (BPH) tissues but 35.9% (23/64) of PCa tissues (P<0.001). There was a significant difference of CMTM5 expression between the two groups of PCa tissues with different Gleason scores (P=0.003), though its expression was not related to the age, clinical stage, and metastatic situation (P>0.05). EGFR was highly expressed in 57.8% (37/64) of PCa tissues, it had statistical significance between EGFR and CMTM5 expressions in PCa tissues. Furthermore, 23 cases (35.9%) had low CMTM5 expression and high EGFR expression. Western blot showed that CMTM5 was undetectable in PCa cells, in which the EGFR expression was upregulated.


CONCLUSIONS
The loss of CMTM5 may participate in the progression of PCa resulting from deregulated EGFR.
Department of Urology, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen 518020, China; Department of Urology, Peking University People's Hospital, Beijing 100044, China.
Ye-qing
YQ
Yuan
Department of Urology, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen 518020, China.
Yi-xiang
YX
Zhang
Department of Urology, Peking University People's Hospital, Beijing 100044, China; Department of Urology, Beijing Jishuitan Hospital, Beijing 100096, China.
Zhen-hua
ZH
Liu
Department of Urology, Peking University People's Hospital, Beijing 100044, China; Department of Urology, Peking University International Hospital, Beijing 102206, China.
Cai-peng
CP
Qin
Department of Urology, Peking University People's Hospital, Beijing 100044, China.
Zheng-zuo
ZZ
Sheng
Department of Urology, Peking University People's Hospital, Beijing 100044, China.
Tao
T
Xu
Department of Urology, Peking University People's Hospital, Beijing 100044, China.
Xiao-feng
XF
Wang
D018925:Chemokines / Q000378:metabolism*; D018450:Disease Progression; D066246:ErbB Receptors / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D062792:MARVEL Domain-Containing Proteins / Q000378:metabolism*; D008297:Male; D011470:Prostatic Hyperplasia / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000378:metabolism*; D025521:Tumor Suppressor Proteins / Q000378:metabolism*; D015854:Up-Regulation
C525020:CMTM5 protein, human; D018925:Chemokines; D062792:MARVEL Domain-Containing Proteins; D025521:Tumor Suppressor Proteins; C512478:EGFR protein, human; D066246:ErbB Receptors